GLP-1 RA Real-World Studies Increasingly Use Negative Controls, Yet Lack Standardized Reporting and Assumption Transparency
Background
Pharmacoepidemiological studies are crucial for evaluating real-world drug effects, particularly for widely adopted medications like glucagon-like peptide-1 receptor agonists (GLP-1 RAs). While these observational studies offer valuable insights into non-indicated clinical outcomes, they are inherently susceptible to residual confounding and systematic bias. Negative controls (NCs) are a key methodological tool designed to detect such biases, yet their application and reporting in applied pharmacoepidemiology remain inconsistent, potentially impacting the reliability of real-world evidence.
Study Design
Researchers conducted a methodological scoping review, systematically searching PubMed and Embase (inception through November 2025) and screening reference lists. They identified 42 studies from 489 records that met inclusion criteria: real-world data, observational framework, GLP-1 RAs as intervention, focus on non-indicated outcomes, and explicit incorporation of negative controls (NCs) for bias detection or validation. The review characterized how NCs were selected, implemented, reported, and interpreted across these studies.
Results
Among the 42 eligible studies identified, the majority were cohort-based, conducted in diabetes-related populations, and utilized electronic health records or administrative claims data. The review found that Negative Control Outcomes (NCOs) were the predominant approach for bias detection, while Negative Control Exposures (NCEs), positive controls, and empirical calibration methods were less frequently employed. An explicit rationale for negative control selection was reported in most studies. > However, a critical finding was that none of the included studies explicitly discussed the underlying assumptions of negative control analysis, highlighting a significant gap in methodological transparency. Most negative control findings were reported as null or consistent with expectations, primarily serving to support the validity or robustness of the main findings rather than materially altering the interpretation of the GLP-1 RA effects on non-indicated outcomes. This suggests NCs are used more for confirmation than for critical re-evaluation.
Key Findings
- 42 real-world observational studies on GLP-1 RAs and non-indicated outcomes incorporated negative controls.
- Negative Control Outcomes (
NCOs) were the dominant approach for bias detection. - None of the included studies explicitly discussed the assumptions underlying negative control analysis.
- Most negative control findings were null, primarily supporting validity rather than altering main interpretations.
- Standardized implementation and transparent reporting of negative controls are currently lacking.
Why It Matters
This scoping review underscores a critical need for enhanced methodological rigor in GLP-1 RA pharmacoepidemiology. For researchers and clinicians relying on real-world evidence, understanding the limitations of bias detection methods is paramount. While negative controls are increasingly adopted to bolster study validity, their inconsistent application and lack of transparent reporting on underlying assumptions mean that some conclusions regarding GLP-1 RA effects on non-indicated outcomes may still be less robust than perceived. Future real-world studies should adopt standardized guidelines for negative control selection, implementation, and interpretation, explicitly detailing their rationale and how findings influence conclusions. This will improve the credibility and interpretability of real-world data, ultimately informing safer and more effective clinical practice.
glp-1-ra
pharmacoepidemiology
observational-study
real-world-data
negative-controls
bias-detection